Marshall Gailen D, Sorkness Christine A
University of Texas Health Science Center, Houston Medical School, USA.
Manag Care. 2004 Mar;13(3):45-50.
To review the characteristics of difficult-to-treat asthma and describe patients who may benefit from therapy with the recently approved humanized monoclonal antiimmunoglobulin E (IgE) antibody, omalizumab.
Up to 20 percent of patients have difficult-to-treat asthma. These patients consume a disproportionate share of asthma care resources. Clinical and economic outcomes can be improved via improved self-management, increased adherence to prescribed therapy, and better compliance to national asthma treatment guidelines. These patients also may benefit from therapies that directly target mechanisms responsible for persistent airway inflammation and elicit favorable clinical responses.
Effective asthma control remains difficult in a small cohort of patients with persistent, severe airway inflammation. Management strategies that improve asthma control and reduce exacerbations can improve clinical outcomes and minimize health care resource utilization.
回顾难治性哮喘的特征，并描述可能从近期获批的人源化抗免疫球蛋白E（IgE）单克隆抗体奥马珠单抗治疗中获益的患者。
高达20%的患者患有难治性哮喘。这些患者消耗了不成比例的哮喘护理资源。通过改善自我管理、提高对规定治疗的依从性以及更好地遵守国家哮喘治疗指南，可以改善临床和经济结果。这些患者也可能从直接针对导致持续性气道炎症的机制并引发良好临床反应的治疗中获益。
一小部分患有持续性严重气道炎症的患者实现有效的哮喘控制仍然困难。改善哮喘控制并减少发作的管理策略可以改善临床结果，并最大限度地减少医疗资源的利用。
